NEW YORK, NY--(Marketwired - Jun 30, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Indiana on behalf of investors who purchased Endocyte, Inc. ("Endocyte" or the "Company") (
For more information, click here: http://zlk.9nl.com/endocyte-ecyt.
The complaint alleges that throughout the Class Period defendants issued misleading statements regarding the efficacy of the Company's experimental drug VYNFINIT, and misrepresented and/or failed to disclose material information regarding the Company's business and financial prospects. In particular it is alleged that Endocyte misrepresented the nature of positive statements made about the drug in a March 21 press release, ultimately capitalizing on the resulting stock price increase to issue a public offering and sell shares at an inflated price.
If you suffered a loss in Endocyte you have until August 25, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/endocyte-ecyt.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
- Company Legal & Law Matters
- United States District Court
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510